Alphatec (NASDAQ:ATEC) Reaches New 12-Month Low Following Weak Earnings

Posted by Francis Steltz on Oct 30th, 2026

Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Free Report) shares hit a new 52-week low during trading on Friday after the company announced weaker than expected quarterly earnings. The stock traded as low as $6.81 and last traded at $7.7010, with a volume of 3,777,722 shares trading hands. The stock had previously closed at $11.37.

The medical technology company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Alphatec had a negative net margin of 13.49% and a negative return on equity of 6,752.24%. The firm had revenue of $221.17 million during the quarter, compared to analysts’ expectations of $225.16 million. During the same quarter in the previous year, the firm posted $0.03 EPS. The firm’s revenue for the quarter was up 12.6% on a year-over-year basis.

More Alphatec News

Here are the key news stories impacting Alphatec this week:

Positive Sentiment: Third-quarter revenue rose 12.6% year over year to $221.17 million, while earnings increased to $0.09 per share from $0.03 a year earlier. However, both figures were below analyst expectations. Alphatec third-quarter earnings report
Positive Sentiment: Management continues to target a 16% adjusted EBITDA margin for 2026, suggesting an emphasis on profitability and operating efficiency despite slower-than-expected revenue growth. Alphatec lowers fiscal 2026 revenue outlook
Neutral Sentiment: The company’s quarterly results show continued commercial growth, but Alphatec remains unprofitable, with a negative net margin and analysts expecting a full-year loss. Alphatec third-quarter and nine-month results
Negative Sentiment: Alphatec lowered its 2026 revenue forecast to $862 million, below the approximately $882 million FactSet estimate. The reduced outlook signals weaker near-term growth than investors had anticipated. Alphatec 2026 revenue outlook
Negative Sentiment: BMO Capital Markets downgraded ATEC from “outperform” to “market perform” and set an $8.00 price target, implying roughly 29.6% downside from the referenced $11.37 price. BMO Capital Markets Alphatec rating

Analysts Set New Price Targets

ATEC has been the topic of a number of research reports. TD Cowen reissued a “buy” rating on shares of Alphatec in a research report on Friday. UBS Group boosted their price objective on shares of Alphatec from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alphatec in a research report on Monday, August 3rd. Needham & Company LLC dropped their target price on Alphatec from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Stifel Nicolaus cut their price target on Alphatec from $16.00 to $13.00 and set a “buy” rating on the stock in a report on Wednesday, July 8th. Twelve investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $17.00.

Check Out Our Latest Report on Alphatec

Insider Activity

In other Alphatec news, CEO Patrick Miles purchased 115,000 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were acquired at an average price of $8.81 per share, for a total transaction of $1,013,150.00. Following the completion of the purchase, the chief executive officer owned 5,893,551 shares of the company’s stock, valued at approximately $51,922,184.31. The trade was a 1.99% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Tyson Marshall sold 8,168 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $9.65, for a total transaction of $78,821.20. Following the transaction, the general counsel owned 630,398 shares in the company, valued at approximately $6,083,340.70. This trade represents a 1.28% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 13.48% of the company’s stock.

Institutional Investors Weigh In On Alphatec

Hedge funds have recently modified their holdings of the company. Bank of America Corp DE grew its holdings in Alphatec by 26.9% in the first quarter. Bank of America Corp DE now owns 2,560,971 shares of the medical technology company’s stock valued at $27,863,000 after purchasing an additional 543,059 shares during the period. Emerald Advisers LLC lifted its stake in Alphatec by 10.4% in the 1st quarter. Emerald Advisers LLC now owns 1,807,307 shares of the medical technology company’s stock valued at $19,664,000 after buying an additional 169,578 shares in the last quarter. Granite Investment Partners LLC boosted its holdings in Alphatec by 4.7% in the 1st quarter. Granite Investment Partners LLC now owns 1,195,156 shares of the medical technology company’s stock worth $13,003,000 after buying an additional 54,043 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its stake in Alphatec by 27.1% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 1,156,826 shares of the medical technology company’s stock valued at $12,586,000 after purchasing an additional 246,773 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY acquired a new position in shares of Alphatec during the 2nd quarter worth approximately $9,413,000. 66.35% of the stock is owned by hedge funds and other institutional investors.

Alphatec Stock Performance

The business has a 50 day simple moving average of $10.18 and a 200-day simple moving average of $10.67. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -10.68 and a beta of 0.78.

Alphatec Company Profile

(Get Free Report)

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.